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II – Abstract 
 
Type 2 diabetes (T2D) is a chronic metabolic disorder that reached 
epidemic proportions, affecting almost 390 million people around the globe. 
Most cases of T2D result from unhealthy eating habits. In fact, consumption of 
high-fat diets and high intake of saturated fat are associated with an increased 
risk of obesity, metabolic syndrome and T2D. Additionally, hypovitaminosis D 
has also been described as a major health problem. Interestingly, a common 
characteristic found in T2D patients is the low levels of serum vitamin D. 
Vitamin D is a fat-soluble hormone that shares common signaling pathways 
with insulin, modulating glucose homeostasis and organs function such as the 
brain, among other things. Given the growing evidence that T2D is a risk 
factor for the development of neurodegenerative disorders, particularly 
Alzheimer’s disease (AD), we hypothesize that high-fat and/or low vitamin D 
diets potentiate brain insulin signaling alterations in T2D brain cortex and 
hippocampus predisposing to neurodegenerative events. To test our 
hypothesis, we evaluated the insulin signaling pathway and its effects in 
synaptic integrity and AD-related hallmarks in brain cortex and hippocampus 
of 6-month-old Goto-Kakizaki (GK) rats, a commonly used non-obese T2D 
animal model, subjected to distinct dietary regimens as follows: 1) GK rats fed 
a standard diet (GK); 2) GK rats fed a low vitamin D diet (GK low vitD); 3) GK 
rats fed a high-fat diet (GK HFD) and 4) GK rats fed a high-fat, low vitamin D 
diet (GK HFD low vitD). Animals were subjected to these diets during 4 
months. 6-month-old Wistar rats were used as control animals. Besides the 
biochemical characterization of the animals, brain cortical and hippocampal 
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homogenates were used to evaluate the protein levels of glucose 
transporters, insulin/insulin-growth factor 1 (IGF-1) levels and respective 
receptors (IR and IGF-1R), vitamin D receptor (VDR), several molecules 
modulated by insulin/IR activation, markers of synaptic integrity and AD-
related hallmarks. GK rats showed increased fasting glycemia and glycated 
hemoglobin (HbA1C) and a decrease in body weight, typical features of this 
animal model. HFD increased body weight and HbA1C, total cholesterol, non-
high-density lipoprotein cholesterol and triglycerides levels. Interestingly, low 
vitD diet attenuated HFD-induced alterations particularly in body weight and 
total cholesterol, non-HDL and triglycerides levels. HFD and low vitamin D 
diet altered brain glucose transporters, particularly the insulin sensitive 
glucose transporter 4 (Glut 4), whose levels in the hippocampus were 
decreased by low vitD and/or HDF while in brain cortex, low vitD increased 
the levels of Glut 4, an effect that was abrogated by the combination with 
HFD. In brain cortex the combination HFD and low vitD decreased the levels 
of VDR and cholesterol and increased IR. Also in brain cortex, low vitD diet 
and HFD per se increased insulin levels while in the hippocampus only HFD 
increased the levels this hormone. HFD also increased phosphorylated insulin 
receptor substrate 2 (IRS2) levels in brain cortex. Additionally, in both brain 
cortex and hippocampus, HFD increased the levels of phosphorylated 
extracellular signal-regulated kinases (ERK) and phosphorylated tau, these 
effects being abrogated by low vitD. Phosphorylated protein kinase B (AKT) 
was decreased by HFD in brain cortex while in the hippocampus the levels of 
this protein were decreased by the combination HFD and low vitD. The levels 
of the phosphorylated form of 5’ adenosine monophosphate-activated protein 
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kinase (AMPK) and active protein kinase A (PKA) were decreased by low 
vitD diet and/or HFD in both brain cortex and hippocampus. In the 
hippocampus, HFD increased the levels of phosphorylated mammalian target 
of rapamycin (mTOR), an effect that was abolished by the combination HFD 
and low vitD. Interestingly, the levels of phosphorylated cAMP response 
element-binding protein (CREB) were significantly increased in brain cortex 
by the combination HFD and low vitD while in the hippocampus the opposite 
effect was observed. The combination of HFD and low vitD also decreased 
the levels of inactive glycogen synthase kinase 3 beta (GSK3) and p35 in the 
hippocampus. No statistically significant alterations were observed in all the 
other parameters analyzed. Our findings demonstrate that high-fat and/or low 
vitD diets affect cerebral insulin signaling pathway. Nevertheless, some 
compensation mechanisms seem to occur to avoid metabolic disturbances-
induced brain damage. 
 
Keywords: Brain cortex and hippocampus, high-fat diet, insulin signaling, low 
vitamin D diet, neurodegeneration, type 2 diabetes 
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III – Resumo 
 
 A diabetes tipo 2 (T2D) é uma doença metabólica crónica que atingiu 
proporções epidémicas, afetando cerca de 390 milhões de pessoas em todo 
o mundo. A maior parte dos casos de T2D resultam de hábitos alimentares 
pouco saudáveis. De facto, a ingestão excessiva de alimentos ricos em 
gorduras, nomeadamente gorduras saturadas, está associada a um aumento 
do risco de obesidade, síndrome metabólico e T2D. A hipovitaminose D 
também está associada a várias doenças. Curiosamente, a T2D está 
normalmente associada a níveis baixos de vitamina D no plasma de 
indivíduos acometidos pela doença. A vitamina D é uma hormona lipossolúvel 
que partilha vias de sinalização com a insulina, modulando a homeostasia da 
glucose e o funcionamento de vários órgãos, como o cérebro, entre outras 
coisas. Uma vez que a T2D é um importante fator de risco para o 
desenvolvimento de doenças neurodegenerativas, nomeadamente a doença 
de Alzheimer (AD), colocamos a hipótese de que uma dieta gorda e/ou uma 
dieta deficiente em vitamina D afeta(m) as vias de sinalização da insulina no 
cérebro diabético predispondo para processos neurodegenerativos. Para 
testar a nossa hipótese, avaliámos as alterações nas vias de sinalização da 
insulina e os seus efeitos na integridade sináptica e marcadores relacionados 
com AD no córtex cerebral e no hipocampo de ratos Goto-Kakizaki (GK), um 
modelo animal não obeso de T2D comummente utilizado, com 6 meses de 
idade, sujeitos a dietas distintas: 1) ratos GK sujeitos a uma dieta regular 
(GK); 2) ratos GK sujeitos a uma dieta deficiente em vitamina D (GK low 
vitD); 3) ratos GK sujeitos a uma dieta gorda (GK HFD) e 4) ratos GK sujeitos 
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a uma deita gorda, deficiente em vitamina D (GK HFD low vitD). Os animais 
estiveram sujeitos a estas dietas durante 4 meses. Foram usados ratos 
Wistar da mesma idade como animais controlo. Além da caracterização 
bioquímica dos animais, foram utilizados homogeneizados de córtex cerebral 
e hipocampo dos ratos para avaliar os níveis proteicos dos transportadores 
de glucose, insulina/fator de crescimento semelhante à insulina 1 (IGF-1) e 
dos respetivos recetores (IR e IGF-1R), recetor da vitamina D (VDR), várias 
moléculas moduladas pela ativação de insulina/IR, marcadores de 
integridade sináptica e marcadores relacionados com AD. Os ratos GK 
apresentaram um aumento da glicemia em jejum, na hemoglobina glicada 
(HbA1C) e uma diminuição do peso corporal, características deste modelo 
animal. A dieta gorda aumentou o peso corporal e os níveis plasmáticos de 
HbA1C, colesterol total, colesterol não-HDL (lipoproteínas de alta densidade) 
e triglicerídeos. Curiosamente, a dieta deficiente em vitamina D atenuou as 
alterações induzidas pela dieta gorda relativamente ao peso corporal e aos 
níveis de colesterol total, colesterol não-HDL e triglicerídeos. A dieta gorda e 
a dieta deficiente em vitamina D alteraram os níveis dos transportadores de 
glucose, particularmente o transportador de glucose 4 (Glut 4), o qual é 
sensível à insulina, cujos níveis no hipocampo foram diminuídos por ambas 
as dietas, independentemente ou em conjunto, enquanto no córtex cerebral, 
a dieta deficiente em vitamina D aumentou os níveis de Glut 4, um efeito que 
foi anulado pela combinação com a dieta gorda. No córtex cerebral a 
combinação da dieta gorda com deficiência em vitamina D diminuiu os níveis 
de VDR e de colesterol e aumentou os níveis de IR. No córtex cerebral, a 
deficiência em vitamina D ou a dieta gorda aumentaram os níveis de insulina 
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enquanto no hipocampo apenas a dieta gorda aumentou os níveis desta 
hormona. A dieta gorda aumentou ainda os níveis do substrato do recetor de 
insulina 2 fosforilado (IRS2) no córtex cerebral. Tanto no córtex cerebral 
como no hipocampo, a dieta gorda aumentou os níveis das proteínas cinase 
regulada por sinais extracelulares fosforilada (ERK) e tau fosforilada, sendo 
estes efeitos anulados pela deficiência em vitamina D. A proteína cinase B 
(AKT) fosforilada foi diminuída pela dieta gorda no córtex cerebral enquanto 
no hipocampo os níveis desta proteína estavam diminuídos pela combinação 
da dieta gorda com deficiência em vitamina D. Os níveis proteicos da 
proteína cinase ativada por 5’ adenosina monofosfato fosforilada (AMPK) e 
da proteína cinase A (PKA) ativa foram diminuídos pela dieta deficiente em 
vitamina D e/ou pela dieta gorda no córtex cerebral e hipocampo. No 
hipocampo, a dieta gorda aumentou os níveis do alvo da rapamicina nos 
mamíferos fosforilado (mTOR), um efeito que foi abolido pela combinação 
da dieta gorda com deficiência em vitamina D. Curiosamente, os níveis do 
elemento de resposta à adenosina monofosfato cíclico fosforilado (CREB) 
foram significativamente aumentados no córtex cerebral pela combinação de 
ambas as dietas, enquanto no hipocampo se observou o efeito oposto. A 
combinação de uma deita gorda e deficiência em vitamina D também 
diminuiu os níveis de cinase 3 beta da sintetase do glicogénio (GSK3) e de 
p35 no hipocampo. Não foram observadas alterações estatisticamente 
significativas nos outros parâmetros analisados. Estes resultados mostram 
que uma dieta gorda e/ou deficiente em vitamina D afeta(m) as vias de 
sinalização da insulina no cérebro. No entanto, foram também observados 
alguns mecanismos de compensação que possivelmente visam limitar a 
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1.1 – Diabetes 
 
Diabetes is a complex chronic metabolic disease with disturbing 
epidemic proportions (Sebastiao et al., 2014), spreading rapidly worldwide. 
With an estimated incidence of 387 million people worldwide, according to the 
International Diabetes Federation (IDF), it is predicted an increase of 205 
millions new cases until 2035 (Figures 1.1 and 1.2). Besides unhealthy 
lifestyle habits that include low physical activity and high calories intake that 
frequently lead to obesity, the increasing incidence of diabetes can also result 
from population growth and increased life expectancy (van Eersel et al., 
2013). 
 
  
Figure 1.1 – Diabetes mellitus incidence worldwide. Prevalence of diabetes in 
2014 and predicted incidence in 2035 (from www.idf.org). 
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According to the National Diabetes Observatory (2014), 13% of the 
Portuguese population between 20 and 79 years old has diabetes, with 
almost 50% (5,7% of this age group) of cases being undiagnosed.  
 
 
Figure 1.2 – Geographic distribution of diabetes. World distribution of diabetes 
cases (from www.idf.org) 
 
There are two main types of diabetes: type 1 diabetes (T1D) and type 2 
diabetes (T2D). Both types are characterized by chronic hyperglycemia 
(Correia et al., 2012) and dysfunctional energy metabolism, due to insulin 
deficiency and/or loss of insulin action (Holt et al., 2010, Umegaki, 2012, 
American Diabetes, 2014). Chronic hyperglycemia leads to long-term 
complications because it negatively affects several organs such as the brain, 
kidney, eyes and heart (Correia et al., 2012, American Diabetes, 2014). 
The incidence of diabetes, particularly T2D, increased dramatically in 
the last years mainly due to unhealthy lifestyles such as poor diets and lack of 
physical exercise (Moreira, 2013). Indeed, a connection between genetics, 
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environmental factors and predisposition and diabetes as been established. 
For example, it has been demonstrated that defects in human leukocyte 
antigen class II genes, that regulate the immune response, may play a role in 
T1D while the hepatocyte nuclear factor 1, which influences insulin 
transcriptional activity and secretion (Holt et al., 2010) may be involved in 
T2D.  
In the next chapters we will give an overview about the two main types 
of diabetes giving focus to T2D and its role as one of the main risk factors for 
neurodegenerative diseases.  
 
1.1.1 – Type 1 diabetes: insulin deficiency 
 
In most people with T1D, the high levels of blood glucose are caused 
by the autoimmune destruction of pancreatic -cells leading to the loss of 
insulin production (Atkinson and Eisenbarth, 2001, Zimmet et al., 2001, Holt et 
al., 2010). Epidemiologically, T1D represents 5 to 10% of all diabetes cases 
(Daneman, 2006) with higher incidence in younger people. However, recent 
studies revealed that T1D could also occur in older people. In fact, 5 to 30% 
of diabetes cases initially diagnosed as T2D were actually T1D (Atkinson and 
Eisenbarth, 2001).  
The incidence of T1D seems to be related not only with genetic but 
also with environmental factors such as diet, psychological stress or viruses, 
among others (Holt et al., 2010, Skyler, 2012).  
The management of T1D is based on constant monitoring of blood 
glucose levels and insulin injections to suppress insulin deficiency, a therapy 
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that is associated with hypoglycemic episodes and glycemic fluctuations, 
which may affect the structure and function of several organs (Daneman, 
2006). 
 
1.1.2 – Type 2 Diabetes: defects in insulin action and 
secretion 
 
T2D is an age-related disease and the most common form of diabetes, 
representing up to 90-95% of all diabetes cases (Umegaki, 2012, Moreira, 
2013, Nunes et al., 2014). Insulin resistance, commonly accompanied by 
progressive impairment in insulin secretion, due to a gradual dysfunction of 
pancreatic -cells, is one of the main characteristics of T2D (Butler et al., 
2003, Umegaki, 2012, Nunes et al., 2014). As a compensation mechanism, 
there is an overproduction of insulin leading to hyperinsulinemia and 
pancreatic -cells exhaustion (Mehran et al., 2012). As a consequence of an 
insulin resistant state, which implies a less effective response to insulin, body 
glucose metabolism is largely affected on target tissues such as the liver, 
adipose tissue, skeletal muscle and also the brain (Umegaki, 2012, Nunes et 
al., 2014). 
Apart from aging, sedentary lifestyle and obesity are also major risk 
factors for T2D development (Stumvoll et al., 2005). In fact, obesity leads to 
an 80-85% increase in the risk of developing T2D through processes like 
inflammation and increased insulin resistance (Stumvoll et al., 2005, Holt et 
al., 2010). In obesity, increased free fatty acids may also interfere with 
pancreatic -cells function due to chronic exposure of these cells to fatty 
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acids, which may impair insulin secretion and decrease insulin biosynthesis 
(Holt et al., 2010). Moreover, a feedback loop occurs with hyperglycemia-
derived reactive oxygen species (ROS) leading to pancreatic -cells 
dysfunction and death, through nuclear factor kappaB (NF-B) activation and 
islet amyloid polypeptide (also known as amylin) accumulation (Butler et al., 
2003, Stumvoll et al., 2005). 
Figure 1.3 – Effects of insulin resistance and hyperglycemia. In normal 
conditions, insulin inhibits lipolysis, decreasing fatty acids release, glucose 
production in the liver and promotes glucose uptake by skeletal muscle and adipose 
tissue. Several factors associated to T2D (e.g. genetic risk factors, adipokines, 
inflammation) affect both insulin secretion and action. Insulin resistance leads to an 
increase in the blood levels of free fatty acids and glucose, among other things, 
aggravating insulin resistance (adapted from Stumvoll et al., 2005). 
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1.1.3 – The complications of diabetes 
 
Diabetes is associated with several macrovascular (stroke, 
cerebrovascular disease, heart disease and peripheral vascular disease) and 
microvascular (retinopathy, nephropathy and neuropathy) complications 
(Daneman, 2006, Holt et al., 2010) (Figure 1.4).  In general, poor glycemic 
control, hypertension and hyperlipidemia are the factors underlying the 
development of these complications (Daneman, 2006, Holt et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 – Diabetes-associated complications. Diabetes has multiple 
deleterious effects throughout the body. Macrovascular alterations are associated 
with stroke, cardiovascular disease and neuropathy while microvascular alterations 
are associated with diabetic retinopathy and nephropathy, among other 
consequences of diabetes (adapted from Skyler, 2012). 
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Of relevance to our work, are diabetic encephalopathy, cognitive 
decline and dementia (Sima, 2010). Brain defects promoted by diabetes 
include alterations in structure and function such as brain atrophy, impaired 
cerebral signal conduction, neurotransmission and synaptic plasticity and 
deficits in learning and memory abilities (Sima, 2010). Diabetes-associated 
alterations in the central nervous system (CNS) have been widely scrutinized. 
There is a hypothesis that states a close association between diabetes, 
specially T2D and neurodegenerative diseases such as Alzheimer’s disease 
(AD). In fact, it is described that T2D patients have a 50% to 150% higher risk 
of developing dementia. Additionally, T2D and AD seem to share several 
features as, for example, impaired glucose metabolism, vascular and 
mitochondrial dysfunction, oxidative stress and amyloidogenesis (Arab et al., 
2011, Correia et al., 2012). In 2010, there were 35,6 million people living with 
dementia with a predicted increase to 115,4 million in 2050, with AD prevailing 
and accounting for 60% to 80% of all cases (Li et al., 2015).  
 As a highly metabolic active tissue, that uses glucose as the main 
energy substrate, brain is expected to be greatly affected by diabetes (Correia 
et al., 2011, Cardoso et al., 2013). 
Indeed, hyperglycemia induces several metabolic alterations leading to 
oxidative phosphorylation (OXPHOS) impairment (Correia et al., 2012, 
Cardoso et al., 2013, Blazquez et al., 2014), increased oxidative stress 
(Cardoso et al., 2013) and damage (Duarte et al., 2000, Correia et al., 2012) 
and advanced glycation end products (AGEs) formation that coupled with free 
radicals exacerbate oxidative damage and an unbalance between pro-
oxidants and antioxidants (Umegaki, 2012). However, some compensatory 
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mechanisms may occur, particularly in the early stages of diabetes, in order to 
overcome diabetes-associated alterations (Santos et al., 2014). 
Patients and animal models of diabetes, particularly T2D, exhibit 
cognitive impairments characterized by a decline in memory and learning 
abilities that increase the risk of developing dementia (e.g. AD) (Cardoso et 
al., 2009, Sima, 2010, Candeias et al., 2012, Carvalho et al., 2013a, 2015, 
Sridhar et al., 2015). These cognitive defects are intimately associated to 
neuronal degeneration and loss (Hussain et al., 2014). 
Insulin resistance seems to be a major contributor for diabetes-related 
brain alterations. Indeed, insulin of both peripheral and central origin, and 
insulin receptors (IR) have been observed in several brain regions and insulin 
signaling play a myriad of functions in the CNS (Cardoso et al., 2009, Duarte 
et al., 2012). This aspect will be further discussed in the next subsection. 
Moreover, oxidative stress has also been described as a characteristic 
of diabetic brain and AD (Correia et al., 2012, Mondragon-Rodriguez et al., 
2013). Previous studies from our laboratory demonstrated that T2D and AD 
rodent models present similar cognitive anomalies, mitochondrial alterations, 
increased levels of oxidative stress and damage, and vascular/endothelial 
dysfunction (Carvalho et al., 2012, 2013a). Interestingly, AD and T2D models 
also presented a defect in nitric oxide (NO)-dependent vasodilation of the 
aorta that was related with increased inflammation and oxidative stress, 
including a significant increase in the levels of the receptor for advanced 
glycation end products (RAGE) (Sena et al., 2015). Also, in AD brain, the 
presence of AGEs is a common observation that is closely associated to 
[Chapter 1 – Introduction] 
 11 
impaired energy metabolism and increase oxidative stress (Dukic-Stefanovic 
et al., 2001).  
 
1.1.4 – Brain insulin and its “neuro” importance 
 
Insulin is a polypeptide mainly synthesized in pancreatic -cells, 
however, a small portion is also synthetized in the brain (Schechter et al., 
1996). Besides its peripheral and crucial function in maintaining glucose 
homeostasis, it is widely known that functional insulin signaling pathways 
regulate a broad spectrum of cellular mechanisms that are essential for 
normal brain functioning (Cardoso et al., 2009, Correia et al., 2011, Candeias 
et al., 2012, 2012, Sebastiao et al., 2014). Due to its neuromodulatory and 
neuroprotective effects, insulin also protects against cognitive impairment 
associated with diabetes, a situation that is more common in the elderly 
(Biessels and Kappelle, 2005, van Eersel et al., 2013, Blazquez et al., 2014). 
Insulin pleiotropic actions are modulated by binding to its receptors. Insulin 
binding to IR promotes an autophosphorylation of the intracellular domain of 
the receptor, activating the intrinsic tyrosine kinase activity. This event triggers 
the phosphorylation of several endogenous substrates, including insulin 
receptor substrates (IRS). Then, two main pathways can be activated: the 
phosphatidylinositol 3-kinase (PI3K) pathway and the mitogen-activated 
protein kinases (MAPK/ERK1/2) pathway.  
The MAPK/ERK1/2 pathway is responsible for the activation of several 
transcription factors, modulating protein expression, and consequently, 
regulating the processes underlying learning and memory (Cardoso et al., 
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2009). In fact, insulin signaling seems to modulate long-term potentiation 
(LTP) and long-term depression (LTD) as well as synaptic plasticity. Besides, 
insulin also regulates neurotransmitter release, the activity of excitatory and 
inhibitory receptors such as glutamate and -aminobutyric acid (GABA) and 
N-methyl-D-aspartate (NMDA) receptors. Moreover, insulin also activates 
protein kinase B (AKT), via PI3K, which regulates pro-survival mechanisms. 
Indeed, AKT regulates the phosphorylation of glycogen synthase kinase 3 
(GSK3) and the mammalian target of rapamycin (mTOR) (Cardoso et al., 
2009). When activated, GSK3 inhibits the activation of several cell survival 
transcription factors, promoting neuronal death. Therefore, GSK3 
inactivation by AKT is crucial for neuronal survival. The PI3K pathway also 
promotes glucose uptake by facilitating the translocation of glucose 
transporter 4 (Glut 4) to the plasma membrane. 
From the above, it is easy to infer an involvement of insulin signaling 
dysfunction in the development of dementia, particularly in T2D patients. 
Prolonged peripheral hyperinsulinemia seems to affect the blood-brain barrier 
(BBB) and IR structure and/or function, inducing an insulin resistance state in 
the brain (Kim et al., 2011a, Correia et al., 2012). Central insulin resistance 
play an important role in cognitive impairment, a phenomenon widely 
documented in diabetic patients and experimental models (Biessels and 
Kappelle, 2005, Candeias et al., 2012, Blazquez et al., 2014, Hussain et al., 
2014, Nunes et al., 2014, Li et al., 2015, Sridhar et al., 2015). In fact, 
alterations in brain insulin signaling is associated with an increased activity of 
GSK3, which potentiates tau protein hyperphosphorylation and amyloid beta 
protein formation, the two neuropathological hallmarks of AD (Cardoso et al., 
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2009) (Figure 1.5). Of extreme importance is also the fact that tau is a 
microtubule-associated protein, needed for the correct axonal transport 
(Cardoso et al., 2009). So, the increased levels of phosphorylated tau will 
compromise transport along the axons (Correia et al., 2011), which may lead 
to degeneration and death of neurons. Altogether, this evidence supports the 
idea of a close link between T2D and insulin resistance and 
neurodegenerative diseases.  
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Figure 1.5 – Insulin signaling pathways. Schematic illustration of the potential 
molecular mechanisms of insulin signaling in the brain. Insulin binds to the insulin 
receptor activating the intrinsic tyrosine kinase, which phosphorylates endogenous 
substrates, such as the insulin receptor substrates (IRS) and Src-homology-2-
containing protein (Shc), leading to the activation of two major downstream signaling 
pathways: 1) the phosphatidylinositol 3-kinase (PI3K) and 2) mitogen-activated 
protein kinases (MAPK/ERK1/2) pathways. PI3K mediates the activation of the 
protein kinase B (AKT) favoring neuronal survival. Activated AKT can interfere with 
the apoptotic machinery, inactivating the pro-apoptotic proteins, BAD, and caspase-
9. Furthermore, PI3K/AKT activation inhibits glycogen synthase kinase 3β (GSK3β), 
which is involved in the triggering of the apoptotic cascade, inhibition of the activation 
of several cell survival transcription factors, tau protein hyperphosphorylation, and 
amyloid-β protein precursor (AβPP) maturation and processing. PI3K/AKT signaling 
cascade also induces the translocation of insulin-sensitive glucose transporter 4 
(Glut 4) to the membrane surface, enhancing glucose uptake. Insulin-mediated PI3K 
signaling pathway is implicated in learning and memory, as well as in synaptic 
plasticity through the regulation of glutamate and GABA (γ-aminobutyric acid) 
receptors trafficking and channel activity. While the GABAergic receptors mediate the 
inhibitory synaptic transmission and the glutamatergic receptors mediate the vast 
majority of the excitatory synaptic transmission, the balance of glutamatergic and 
GABAergic transmissions is required to maintain normal brain function. Moreover, 
activation of excitatory glutamatergic synapses induces Ca2+ influx at postsynaptic 
sites, where it acts as a second messenger. Insulin is also able to active the 
MAPK/ERK1/2 signaling pathway, which is responsible for the activation of several 
transcription factors that alter protein expression. In summary, insulin has an 
important role in the regulation of neuronal cell survival/death, synaptic plasticity, 
learning and memory (adapted from Cardoso et al., 2009). 
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1.2 – Vitamin D: one hormone with multiple functions 
 
The fat-soluble vitamin D can be found in two forms: ergocalciferol or 
vitamin D2, present essentially in plants and some fish, and cholecalciferol or 
vitamin D3, produced in the skin upon sunlight exposure (Kulie et al., 2009, 
Thacher and Clarke, 2011, Vuolo et al., 2012, DeLuca et al., 2013, Eyles et 
al., 2013). Vitamin D metabolization begins with the interaction of ultraviolet 
(UV) B radiation (290-315 nM) with 7-dehydrocholesterol present in 
epidermis. After a spontaneous isomerization, cholecalciferol is formed and 
enters the circulation, being transported by vitamin D binding protein (DBP) 
(Kulie et al., 2009). To achieve its active form, vitamin D suffers two 
hydroxylation steps. The first one, occurs in the liver by 25-hydroxylase 
action, which produces a more stable form of vitamin D, the 25-
hydroxyvitamin D (25(OH)D), commonly used to assess vitamin D status in 
humans (Eyles et al., 2013). Then, a second hydroxylation occurs in different 
organs, including the brain, producing the active form of vitamin D, 1,25-
dihydroxyvitamin D [1,25(OH)2D] through the action of 1-hydroxylase 
(Mathieu and Badenhoop, 2005, Kiraly et al., 2006, Eyles et al., 2013). 
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Figure 1.6 – Vitamin D metabolism. Vitamin D is taken up from food (vitamin D2 
and D3) or synthesized in the skin [sun light with the photon energy wavelength of 
290–315 nm causes photolysis of 7-dehydrocholesterol (7-DHC; provitamin D3) to 
pre-vitamin D3, the immediate precursor in the biosynthetic pathway to vitamin D3]. 
In the circulation, all vitamin D metabolites are bound to vitamin D-binding protein 
(DBP). To become active, vitamin D3 is hydroxylated first in the liver (via 25-
hydroxylase) and successively in the kidney (and other organs via 1α-hydroxylase) to 
its final form, 1,25(OH)2D3. Note that macrophages and other cells are also capable 
of hydroxylate vitamin D to 1,25(OH)2D3, thereby facilitating locally regulated tissue 
concentrations (adapted from Mathieu and Badenhoop, 2005). 
 
 
In order to exert its functions vitamin D needs to bind its specific 
receptor (VDR), a member of nuclear hormone receptors. When activated, 
VDR acquires a heterodimeric form and interacts with vitamin D response 
elements (VDREs), specific deoxyribonucleic acid (DNA) sequences normally 
in the promoter region, regulating transcription processes (Deeb et al., 2007, 
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Bikle, 2009, Vuolo et al., 2012). Furthermore, besides its genomic signaling 
(through interaction with nuclear VDR and consequent interaction with 
VDREs, resulting in gene transcription or repression) vitamin D can also exert 
its action through non-genomic signaling [through interaction with caveolae or 
1,25D3 MARRS (membrane-associated rapid response steroid) binding] 
resulting on a signaling cascade with activation of second messengers 
systems, as for example PI3K and MAPK pathways. Another example are, 
Rapidly accelerated fibrosarcoma/MAPK second messenger that can be 
activated and promote a crosstalk with the nucleus, leading to the previous 
mentioned genomic effects (Figure 1.7) and extracellular signal-regulated 
kinase (ERK) activation that may also improve transcriptional activity of VDR 
(Vuolo et al., 2012).  
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Figure 1.7 – Genomic and non-genomic effects of vitamin D. 1,25(OH)2D (active 
vitamin D) interacts with the vitamin D receptor (VDR) localized in the nucleus to 
generate genomic effects or in caveolae of the plasma membrane to generate non-
genomic effects (rapid responses, RR). Moreover, 1,25(OH)2D can directly interact 
with a novel receptor for 1,25(OH)2D called 1,25D3 MARRS (membrane-associated, 
rapid response steroid-binding). Binding of 1,25(OH)2D at plasma membrane may 
activate one or more second messenger systems, including phospholipase C (PLC), 
protein kinase C (PKC), G protein-coupled receptors, or PI3K. Possible outcomes 
include opening of the voltage-gated calcium or chloride channels or generation of 
second messengers. Some of these second messengers, particularly RAF/MAPK, 
may modulate a crosstalk with the nucleus for gene expression regulation (adapted 
from Vuolo et al., 2012). 
 
Vitamin D plays an important role throughout the organism with its 
deficiency being a potential risk factor for obesity (Kiraly et al., 2006) and the 
development of T2D (Menon et al., 2013), as well as for the development of 
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cognitive impairment and dementia, such as Parkinson’s disease (PD) and 
AD (Evatt et al., 2008, Johansson et al., 2013, Littlejohns et al., 2014). 
Indeed, cross-sectional studies showed that patients with one of these 
diseases frequently present hypovitaminosis D (Annweiler et al., 2012, 
Johansson et al., 2013, Annweiler et al., 2014). This relation probably arises 
from vitamin D important functions in mediating insulin synthesis and 
secretion, insulin sensitivity (Norman et al., 1980, Mathieu et al., 2005a, 
Chagas et al., 2012) and modulating inflammatory process, characteristic of 
both diabetes and AD as well as its neuroprotective and neurotrophic actions 
(Kiraly et al., 2006, Harms et al., 2011, DeLuca et al., 2013, Eyles et al., 
2013). 
Vitamin D is widely known for its role in calcium homeostasis and bone 
metabolism, enhancing calcium absorption in the intestines and increasing 
calcium mobilization to the bone, activating osteoblasts and osteoclasts, thus 
improving bone density (Thacher and Clarke, 2011). On the other hand, 
increasing evidence reveals that vitamin D can influence vital functions in 
several organs, such as the brain and pancreas (Mathieu and Badenhoop, 
2005, Kulie et al., 2009, Eyles et al., 2013). Previous studies showed that 
vitamin D reduces cardiovascular disease and hypertension incidence due to 
an interaction with renin-angiotensin system, a decrease in coagulation and 
modulates vascular smooth muscle cells proliferation (Thacher and Clarke, 
2011, Danik and Manson, 2012). Additionally, it seems to have great influence 
in the immune system, playing a role in reducing the risk of cancer 
development (Vuolo et al., 2012) and inhibits T-cells proliferation and 
cytokines transcription (Danik and Manson, 2012). The anti-proliferative and 
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differentiation effects of vitamin D are a target of attention given its potential in 
cancer prevention or treatment (Bikle, 2009). It was also shown that vitamin 
D, in keratinocytes, is capable of promoting UV-induced DNA damage repair 
(Bikle, 2009). 
Eyles and coworkers (2005) showed that both VDR as well as 1-
hydroxylase are present in several regions of the brain, suggesting that 
vitamin D may have an important role at CNS (Kiraly et al., 2006, DeLuca et 
al., 2013). In agreement, it was already described that vitamin D has 
neurotrophic properties in both developing and adult brain (Eyles et al., 2005) 
and could be involved in neurotransmission, neuroplasticity and 
neuroprotection. Recently, it was postulated that probably those effects may 
last longer than before assumed through epigenetic regulation and metabolic 
imprinting (DeLuca et al., 2013). Moreover, also differentiation, maturation 
and growth seem to be modulated by 1,25(OH)2D action. Indeed, 1,25(OH)2D 
upregulates the production of growth factors like glial cell line-derived 
neurotrophic factor (GDNF), nerve growth factor (NGF) and mediates the 
synthesis of a long range of neurotransmitters (Eyles et al., 2013). For 
example, GDNF can increase the differentiation of dopaminergic neurons in 
animal models of PD treated with 1,25(OH)2D. Indeed, vitamin D seems to 
attenuate neurotoxicity induced by 6-hydroxydopamine, possibly through its 
capacity of enhancing GDNF expression (Wang et al., 2001). Furthermore, 
vitamin D can also be a neuroprotective agent upregulating the expression of 
several neurotrophin factors such as neurotrophin-3 (NT-3), responsible for 
the protection of nerve transmission. Neurotrophins are important in spatial 
navigation and when they are downregulated, spatial navigation, learning and 
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processing events are affected (Buell and Dawson-Hughes, 2008). Moreover, 
neuroplasticity regulation by vitamin D occurs through transcription regulation 
of multiple genes linked to cytoskeleton maintenance, mitochondrial function, 
synaptic plasticity and cell growth and proliferation (DeLuca et al., 2013). 
Also, vitamin D exerts neuroprotective and detoxificant functions concerning 
to oxidative and nitrosative stress, inhibiting the synthesis of inducible nitric 
oxide synthase (iNOS) (Garcion et al., 1997), increasing glutathione levels 
(Kiraly et al., 2006, Buell and Dawson-Hughes, 2008), a powerful antioxidant, 
and modulating L-type sensitive calcium channels (Buell and Dawson-
Hughes, 2008). iNOS is capable of generate NO that is associated with 
inflammatory diseases (Garcion et al., 1997) and vitamin D deficiency 
enhances nitrosative stress (Keeney et al., 2013). As a major calcium 
regulator, vitamin D prevents the excitotoxicity promoted by excess calcium 
levels associated with aging and age-related diseases (Buell and Dawson-
Hughes, 2008, DeLuca et al., 2013). Also, increase in acetylcholine levels in 
the brain due to an increase in choline acetyltransferase activity was showed 
after a treatment with vitamin D (Sonnenberg et al., 1986). Given the major 
role of vitamin D in neuronal development it is legitimate to conclude that 
vitamin D deficiency during young age, or even gestational stage, could have 
repercussions in the elderly, specifically related with cognitive impairment and 
neurodegenerative disorders development. In fact, epidemiological studies 
reveal that AD patients present low plasmatic levels of vitamin D (Przybelski 
and Binkley, 2007, Evatt et al., 2008, Littlejohns et al., 2014), while low 
concentrations of vitamin D appear to impair brain function (Holick, 2015) and 
people with hypovitaminosis D are more prone to present cognitive 
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dysfunctions (Annweiler et al., 2014). Moreover, several studies reveal that 
vitamin D optimal concentration improves neuronal and cognitive function in 
rats (Annweiler et al., 2012, Briones and Darwish, 2012, Latimer et al., 2014) 
through anti-inflammatory actions, regulation of neurotrophic agents, choline 
acetyltransferase (Annweiler et al., 2014) and calcium/calmodulin-dependent 
protein kinase IIδ  (CaMKIIδ) activity (Latimer et al., 2014). For instance, this 
kinase activates adenosine 3’,5’-cyclic monophosphate (cAMP) response 
element binding protein (CREB), enhancing synaptic strength and memory 
formation and improving neurogenesis and dendritic outgrowth by potentiating 
brain-derived neurotrophic factor (BDNF) (Latimer et al., 2014) (Figure 1.8). 
Also, vitamin D may play a role in decreasing A levels in the brain since it 
stimulates macrophages and phagocytosis involved in the clearance of this 
peptide (Durk et al., 2014).  
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Figure 1.8 – Potential neuroprotective effects of vitamin D. Vitamin D has many 
neuroprotective effects contributing to the maintenance of neuronal function and 
preventing the development of neurodegenerative disorders. This large range of 
actions may be implicated in amyloid beta peptide (A) clearance, through 
phagocytosis, and regulation of calcium levels by the prevention of excitotoxic 
events. Vitamin D has also antioxidant actions, by the increase of glutathione levels 
and anti-inflammatory potential. Finally, the regulation of acetylcholine levels, a 
neurotransmitter important in learning and memory formation and the regulation of 
neurotrophic factors are also mediated by vitamin D (adapted from Annweiler et al., 
2014). 
 
 
1.2.1 – Vitamin D deficiency and the incidence of T2D: are 
they related? 
 
Low levels of plasma vitamin D were already described in some 
longitudinal observational studies as a predictive factor for T2D development. 
However, the existence of epidemiologic studies is still scarce and it remains 
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a controversial subject (Forouhi et al., 2008, Knekt et al., 2008, Pittas and 
Dawson-Hughes, 2010, Mitri et al., 2011, Peeyush Kumar et al., 2011, Kabadi 
et al., 2012, Kostoglou-Athanassiou et al., 2013, Hirani et al., 2014, Nigil 
Haroon et al., 2015). Indeed, vitamin D has been described as a modulator of 
blood glucose levels, insulin secretion mediated by glucose and as a regulator 
of calcium levels, important to promote insulin sensitivity in target tissues 
(Muscogiuri et al., 2012, Sung et al., 2012, Alkharfy et al., 2013, Bachali et al., 
2013, Pilz et al., 2013, Badawi et al., 2014, Bellan et al., 2014). So, vitamin D 
deficits are linked to diabetes, specifically to T2D (Norman et al., 1980, 
Bourlon et al., 1999, Mathieu et al., 2005a). Moreover, insulin synthesis was 
shown to improve in the presence of higher levels of 1,25(OH)2D (Mathieu et 
al., 2005a) demonstrating a connection between insulin and vitamin D actions. 
When administered to obese people, vitamin D seems to improve insulin 
sensitivity, mainly due to its anti-inflammatory properties and may also 
improve insulin secretion and insulin receptor expression (Peeyush Kumar et 
al., 2011, Alkharfy et al., 2013). Moreover, it also seems to play an important 
role in reducing lipid profile in obese diabetic patients (Eftekhari et al., 2014).  
Although it is widely shown that vitamin D has positive actions 
throughout the body, supplementation with vitamin D in diabetes patients 
remains a controversial question with studies revealing the inexistence of 
benefits in parameters such as inflammatory markers, glycemic control and 
insulin sensitivity (Jorde and Figenschau, 2009, Kampmann et al., 2014, Krul-
Poel et al., 2014). 
As discussed above, a connection between T2D and dementia do 
exist. Despite the observation that T2D and dementia, including AD, are 
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characterized by low levels of vitamin D, as far as we know, no studies exist 
concerning the impact of vitamin D deficiency in T2D brain. Due to the 
crosstalk of insulin and vitamin D pathways, we hypothesize that vitamin D 
deficiency may exacerbate brain alterations promoted by the insulin resistant 
state that characterizes T2D. 
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2.1 – Objectives 
 
As abovementioned, high-fat intake and vitamin D deficiency increase 
the risk of insulin resistance, T2D and neurodegenerative diseases. 
Appropriate insulin signaling is required for normal brain functioning and 
disturbances in its pathways have been implicated in several 
neurodegenerative processes. 
In this line, this study aimed to uncover the effects of high-fat and/or 
low vitamin D diets in the brain of T2D rats, putting the focus on brain insulin 
signaling. Because AD-related hallmarks and synaptic integrity depend on 
insulin signaling, these possible alterations were also studied in T2D brains. 
 For this purpose we evaluated the insulin signaling pathway and its 
effects in synaptic integrity and AD-related hallmarks in brain cortex and 
hippocampus of T2D Goto-Kakizaki (GK) rats subjected to distinct diets, 
during 4 months, as follows: 1) GK rats fed a standard diet (GK); 2) GK rats 
fed a low vitamin D diet (GK low vitD); 3) GK rats fed a high-fat diet (GK HFD) 
and 4) GK rats fed a high-fat, low vitamin D diet (GK HFD low vitD).
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3.1 – Materials 
 
All the chemicals were of the highest grade of purity commercially 
available. The specific enzyme-linked immunosorbent assay (ELISA) kits, 
antibodies, reagents and other specific materials used in this work are 
described in the following subsections. 
 
3.2 – Animals and experimental design 
 
Male wistar and GK rats (2-month-old) were maintained in our animal 
facilities (Faculty of Medicine, University of Coimbra) under controlled light (12 
hours day/night cycle) and humidity with ad libidum access to food and water. 
GK rats are a non-obese type 2 diabetes animal model, characterized 
by an early life development of the disease, presenting mild hyperglycemia, 
insulin resistance and secondary hyperinsulinemia (Santos et al., 2014). GK 
rats were randomly divided into four groups and fed: 1) regular (standard) diet 
(GK), 2) vitamin D deficient diet (GK Low vitD), 3) high-fat diet (GK HFD) and 
4) high-fat diet deficient in vitamin D (GK HFD Low vitD), for four months 
(Figure 3.1). Wistar rats were fed with a regular diet and used as control 
group. 
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Figure 3.1 - Experimental design. GK rats were randomly divided into four groups 
and fed 1) regular (standard) diet; 2) vitamin D (vitD) deficient diet; 3) high-fat diet; 4) 
high-fat diet deficient in vitamin D. The animals were sacrificed four months after the 
treatment.  
 
Diets were purchased from Scientific Animal Food & Engineering 
(SAFE) and the diets composition is described in tables 3.1 and 3.2. 
According to procedures approved by the Federation of Laboratory 
Animal Science Association (FELASA) and Directive 2010/63/EU, four months 
after the treatment, animals were anesthetized with ketamine/chlorpromazine 
[ketamine chloride (75 mg/kg, im, Parke-Davis, Ann Arbor, MI, USA) and 
chlorpromazine chloride (2,65 mg/kg, im, Lab. Vitória, Portugal)] and 
sacrificed by decapitation. Animals’ manipulation was performed by qualified 
persons (accredited by FELASA and Direção Geral de Alimentação e 
Veterinária, DGAV).  
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Table 3.1 – Standard diet composition 
 
 
Table 3.2 – Vitamin D deficient high-fat diet composition 
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3.3 – Animals’ biochemical characterization 
 
Immediately before animal sacrifice, and following body weight 
measurement, blood glucose levels were determined by a glucose oxidase 
reaction, using a commercial glucometer (Glucometer – Elite Bayer, Portugal) 
and compatible reactive tests (Ascencia Elite Bayer, Portugal) and blood 
glycated hemoglobin (HbA1C) levels were determined using a commercial 
A1CNow System (Bayer HealthCare, 81611395).  
Serum fasting plasma lipids [total and high-density lipoprotein (HDL) 
cholesterol and triglycerides] were evaluated by using commercial kits in an 
automatic system (Olympus-Diagnóstica Portugal, Produtos de Diagnóstico 
SA, Portugal) in blood collected by heart puncture in deeply anesthetized rats. 
Serum was obtained by centrifugation of blood at 13 000 rpm for 10 minutes 
at 4ºC (Sigma 2-16 PK centrifuge). 
 
3.4 – Brain samples homogenization 
 
The brain cortices and hippocampus were separately homogenized in 
a lysis buffer (Cell Signaling #9803) containing 20 mM Trizma hydrochloride 
(Tris-HCl; pH 7.5), 150 mM sodium chloride (NaCl), 1 mM disodium salt of 
ethylenediaminetetraacetic acid (Na2EDTA), 1 mM ethylene glycol tetraacetic 
acid (EGTA), 1% Triton, 2.5 mM sodium pyrophosphate (Na4P2O7), 1 mM 
beta-glycerophosphate, 1 mM sodium orthovanadate (Na3VO4), 1 µg/ml 
leupeptin supplemented with a protease and phosphatase inhibitors cocktail 
from Roche, 0.1 M phenylmethanesulfonylfluoride (PMSF) and 0.2 M 
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dithiothreitol (DTT). To favor disruption, the homogenates were frozen in liquid 
nitrogen and thawed 3 times followed by centrifugation at 14 000 rpm for 10 
minutes at 4ºC (Eppendorf Centrifuge 5415C). The supernatants were 
collected and stored at -80ºC. 
 
3.5 – Protein concentration determination 
 
Protein concentration was determined through bicinchoninic acid (BCA) 
protein assay (Pierce Thermo Fisher Scientific, Rockford, IL). This 
quantification method is based on a colorimetric detection of protein 
concentration, using biuret reaction principle, in which protein is capable of 
reducing cuprous (Cu2+) to cuprous cation (Cu1+) in an alkaline medium and a 
highly sensitive detection of the (Cu1+), using a reagent containing BCA. 
Bovine serum albumin (BSA) is used to perform a standard curve, preparing a 
series of dilutions of known protein concentrations. 
 
3.6 – Western Blot Analysis 
 
The samples (50g of protein) were resolved by electrophoresis in 8%, 
10% or 15% sodium dodecyl sulfate (SDS)–polyacrylamide gels, according 
the molecular weight of proteins of interest, and then transferred into 
polyvinylidene difluoride (PVDF) membranes. Non-specific bindings were 
blocked by gently agitating the membranes in 5% BSA and 0.1% Tween in 
Tris-buffered saline (TBS-T) for 1 hour at room temperature. Subsequently, 
membranes were incubated with the respective primary antibodies (table 3.3) 
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diluted in 1% BSA, overnight at 4ºC, with gentle agitation. After, membranes 
were washed (3x 5 minutes) with 0,05% TBS-T, and then incubated with the 
specific secondary antibody for 2 hours (table 3.4), at room temperature, with 
gentle agitation. After incubation, membranes were washed (3x 5 minutes) 
with TBS-T and incubated with enhanced chemifluorescence (ECF) for 5 
minutes. The specific bands of immunoreactive proteins were visualized in a 
VersaDoc Imaging System (Bio-Rad) and the density of protein bands were 
calculated using the Quantity One Software (Bio-Rad).  
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Table 3.3 - Primary antibodies 
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Table 3.4 - Secondary antibodies 
 
 
3.7 – Evaluation of adenosine 3’,5’-cyclic monophosphate 
(cAMP) levels 
 
cAMP levels were determined using a commercial colorimetric kit 
(cAMP Direct Immunoassay Kit, BioVision Incorporated, #K371-100), 
according to the manufacturer’s instructions. The kit utilizes recombinant 
Protein G coated 96-well plate to efficiently anchor cAMP polyclonal antibody 
on to the plate. cAMP - horseradish peroxidase (HRP) conjugate directly 
competes with cAMP from sample binding to the cAMP antibody on the plate. 
After incubation and washing, the amount of cAMP-HRP bound to the plate 
was determined by reading the optical density (OD) at 450 nm. The 
absorbance is inversely proportional to the concentration of cAMP in samples. 
The results are expressed as pmol/mg of protein. 
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3.8 – Evaluation of protein kinase A (PKA) levels 
 
PKA levels were assessed using a commercial kit (PKA kinase activity 
kit, Enzo Life Science Inc., ADI-EKS-390A), following the manufacturer’s 
instructions. In the assay, the substrate, which is readily phosphorylated by 
PKA, is pre-coated on the wells of the provided PKA substrate microtiter plate. 
The samples were added to the appropriate wells followed by the addition of 
ATP to initiate the reaction. The kinase reaction was terminated and a 
phosphospecific substrate antibody was added to the wells, which binds 
specifically to the phosphorylated peptide substrate. The phosphospecific 
antibody was subsequently bound by a peroxidase conjugated secondary 
antibody. The assay was developed with tetramethylbenzidine (TMB) 
substrate and a color developed in proportion to PKA phosphotransferase 
activity. The color development was stopped with acid stop solution and the 
intensity of the color was measured in a microplate reader at 450 nm (OD). 
The results are expressed as ng/mg of protein. 
 
3.9 – Evaluation of insulin levels 
 
Insulin levels were measured using a commercial colorimetric kit 
[Insulin (mouse/rat) EIA kit, Bertin pharma, A05105], following the 
manufacturer’s instructions. In brief, insulin levels were determined based in a 
competition mechanism between unlabelled insulin present in samples and 
acetylcholinesterase (AChE), linked to rat insulin (tracer), for specific binding 
sites in Guinea-Pig anti-rat insulin antiserum sites. Samples were added to 
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anti-insulin antibody coated plate followed by the addition of an enzymatic 
substrate for AchE (Ellman’s reagent) to initiate the reaction. Color intensity 
was measured at 450 nm (OD). The color intensity is inversely proportional to 
the amount of insulin in the samples. The results are expressed as ng/mg of 
protein. 
 
3.10 – Evaluation of insulin-like growth factor 1 (IGF-1) 
levels 
 
IGF-1 levels were determined using a commercial available kit (Rat 
insulin-like growth factor I ELISA Kit, Biosensis - BEK-2150-2P), following 
the manufacturer’s instructions. The IGF-I Kit is a sandwich ELISA. The 
capture antibody is a monoclonal rat IGF-I antibody pre-coated onto the 96-
well strip plates provided in the kit. Rat test samples and standards of known 
IGF-I concentration were added to these wells and allowed to complex with 
the bound IGF-I antibody. A biotinylated rat IGF-I polyclonal antibody was 
then added. This detection antibody bound to the antigen thus completing the 
sandwich. After washing, an enzyme Avidin-Biotin-Peroxidase complex (ABC) 
was added for binding to the second antibody. The peroxidase substrate TMB 
was added to induce a colored reaction product. The intensity of this colored 
product, read at 450 nm (OD), is directly proportional to the concentration of 
IGF-I present in the samples. The results are expressed as pg/mg of protein. 
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3.11 – Evaluation of amyloid beta (A)1-42 levels 
 
 A1-42 levels were assessed using a commercial available kit (Amyloid 
beta 42 ELISA kit, mouse, Invitrogen, life technologies, #KMB3441), 
according to the manufacturer’s instructions. This kit is a solid phase 
sandwich ELISA. A monoclonal antibody to the NH2-terminus of mouse Aβ 
has been coated onto the wells of the microtiter strips provided. Samples, 
including standards of known mouse Aβ42 content and control specimens, 
were pipetted into these wells. The Aβ antigen binds to the immobilized 
(capture) antibody. After washing, a rabbit monoclonal antibody specific for 
the COOH-terminus of the A1-42 sequence was added to the wells. Bound 
rabbit antibody was detected by the use of a HRP-labeled anti-rabbit antibody. 
After removal of excess anti-rabbit antibody, a substrate solution was added, 
which was acted upon by the bound enzyme to produce color. The intensity of 
this colored product (450 nm) is directly proportional to the concentration of 
A1-42. The results are expressed as pg/mg of protein. 
 
3.12 – Evaluation of cholesterol levels 
  
Brain cholesterol levels were measured using a commercial available kit 
(Cholesterol RTUTM, bioMérieux SA) following the manufacturer’s instructions. 
The principle of the reaction is based on the production of hydrogen peroxide 
(H2O2) in cholesterol oxidation by cholesterol oxidase. In a first step, 
cholesterol esters are hydrolyzed to free cholesterol and fatty acids by 
cholesterol esterase. Then, free cholesterol is oxidized by cholesterol oxidase, 
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producing cholest-4-en-3-one and hydrogen peroxide. Finally, quinoneimine 
dye is formed when H2O2 oxidizes phenol and 4-aminoantipyrine. Briefly, 1 ml 
of the kit’s reagent [3-(N-morpholino)propanesulfonic acid (MOPS) buffer (pH 
7), phenol, sodium cholate, magnesium chloride, a surfactant agent, 4-
aminoantipyrine, peroxidase, cholesterol oxidase and cholesterol esterase) 
was added to 10 l of sample. Color intensity was measured (500 nm) after 
10 minutes of incubation at room temperature. Color intensity is directly 
proportional to the cholesterol concentration present in the samples. The 
results are expressed as g/mg of protein. 
 
3.13 – Statistical analysis 
 
Results are presented as mean  SEM of the number of the indicated 
number of animals. Statistical significance was determined using the two-way 
analysis of variance ANOVA test for multiple comparisons, followed by the 
post-hoc Tukey test. A p-value <0.05 was considered statistically significant.
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4.1 – Characterization of the experimental animals 
 
 We measured several T2D-associated parameters in order to validate 
our experimental models. We observed an increase in fasting glycemia and 
HbA1C and a significant decrease in body weight in all groups of GK rats, 
characteristic of this animal model, when compared with Wistar control group 
(Table 4.1). Nevertheless, HFD promoted a more pronounced increase in 
HbA1C levels and body weight. Also, HFD induced a significant increase in 
total cholesterol levels, mainly associated with the increase in non-high 
density lipoproteins (non-HDL) cholesterol, as well as in triglycerides levels 
(Table 4.1). Interestingly, the deficiency in vitD attenuated HFD-induced 
alterations particularly body weight and total cholesterol, non-HDL and 
triglycerides levels (Table 4.1). No significant alterations were observed in 
brain weight (Table 4.1). 
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Table 4.1 – Animals Characterization 
 
Data shown are the means ± SEM of 7-8 animals from each condition studied. 
Statistical significance: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 when compared 
with Wistar rats; $p<0.05; $$$p<0.001; $$$$p<0.0001 when compared with GK rats; 
##p<0.01; ###p<0.001; ####p<0.0001 when compared with GK Low vitD; &p<0.05 when 
compared with GK HFD. 
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4.2 – High-fat and low vitD diets alter glucose 
transporters levels 
 
In the brain we can found the insulin sensitive Glut 4, the partially 
insulin sensitive Glut 1 and the insulin insensitive Glut 3. Concerning Glut 1, 
no significant alterations were observed in the brain cortex of all experimental 
groups while low vitD alone increased significantly the levels of Glut 1 in the 
hippocampus (Figure 4.1 A and B). 
 
Figure 4.1 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus Glut 1 levels. Brain cortex (A) and hippocampus (B) Glut 1 levels 
and western blot representative images (C). Data shown are the means ± SEM of 6 
animals from each condition studied. Statistical significance: *p<0.05. 
 
Furthermore, in brain cortex Glut 3 levels were significantly increased 
in HFD low vitD rats when compared with GK low vitD rats (Figure 4.2 A). 
Curiously, in the hippocampus Glut 3 levels were significantly decreased by 
HDF alone or in combination with low vitD (Figure 4.2 B). 
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Figure 4.2 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus Glut 3 levels. Brain cortex (A) and hippocampus (B) Glut 3 levels 
and western blot representative images (C). Data shown are the means ± SEM of 6 
animals from each condition studied. Statistical significance: *p<0.05; **p<0.01. 
  
Concerning the insulin-sensitive Glut 4, in brain cortex a significant 
decrease was observed in HFD and HFD low vitD groups when compared 
with GK low vitD group (Figure 4.3 A). In the hippocampus, all dietary 
regimens decreased the levels of this transporter (Figure 4.3 B). 
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Figure 4.3 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus Glut 4 levels. Brain cortex (A) and hippocampus (B) Glut 4 levels 
and western blot representative images (C). Data shown are the means ± SEM of 6 
animals from each condition studied. Statistical significance: *p<0.05; **p<0.01; 
***p<0.001. 
 
4.3 – High-fat and low vitD diets decrease vitamin D 
receptor expression 
 
 In order to exert its effects, vitamin D binds to VDR, activating a 
signaling cascade that includes PI3K (p110) activation. A slight increase of 
VDR levels was observed in brain cortex of HFD group, although it was not 
statistically significant when compared with GK rats group (Figure 4.4 A). 
However, in the hippocampus, no significant alterations were observed in the 
same experimental group (Figure 4.4 B). Interestingly, in both brain cortex 
and hippocampus a decrease in VDR levels was observed in animals 
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exposed to low vitD and HFD, when compared with the HFD group, although 
only statistically significant in brain cortex (Figure 4.4 A and B).  
 
Figure 4.4 – Effect of high-fat and/or low vitD diets in VDR levels. Brain cortex 
(A) and hippocampus (B) VDR levels and western blot representative images (C). 
Data shown are the means ± SEM of 7 animals from each condition studied. 
Statistical significance: **p<0.01.  
 
4.4 – The combination of low vitD and high-fat diet 
increases insulin receptor levels in brain cortex  
 
 The binding of a ligand to its receptor is a crucial step to signaling 
pathways activation. Our results showed that in brain cortex, although low vitD 
or HFD per se did not affect IR levels, the combination of low vitD and HFD 
induced a significant increase in IR levels (Figure 4.5 A). However, no 
significant alterations in the expression of IR in hippocampus were observed 
(Figure 4.5 B).  
[Chapter 4 – Results] 
 53 
 
Figure 4.5 – Effect of high-fat and/or low vitD diets in IR levels. Brain cortex (A) 
and hippocampus (B) IR levels and western blot representative images (C). Data 
shown are the means ± SEM of 7 animals from each condition studied. Statistical 
significance: *p<0.05. 
 
In agreement with IGF-1 levels, also IGF-1R levels were not 
significantly affected in any of the experimental groups (Figure 4.6 A and B). 
 
Figure 4.6 – Effect of high-fat and/or low vitD diets in IGF-1R levels. Brain cortex 
(A) and hippocampus (B) IGF-1R levels and western blot representative images (C). 
Data shown are the means ± SEM of 7 animals from each condition studied.  
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4.5 – High-fat and low vitD diets promote brain insulin 
levels increase but not in IGF-1 levels 
 
 Insulin and IGF-1 are two hormones closely associated with T2D due 
to their major role in glucose utilization and metabolism. In the brain, they 
modulate neuronal excitability, nerve cell metabolism and cell survival. An 
increase in insulin levels in brain cortex was observed in GK rats exposed to 
HFD and low vitD diets when compared with GK rats exposed to a standard 
diet (Figure 4.7 A).  In the hippocampus, low vitD diet, by itself, did not 
increase insulin levels. However, HFD or HFD combined with low vitD, led to 
an increment in insulin levels (Figure 4.7 B). 
 
 
Figure 4.7 – Effect of high-fat and/or low vitD diets in insulin levels. Brain cortex 
(A) and hippocampus (B) insulin levels. Data shown are the means ± SEM of 7 
animals from each condition studied. Statistical significance: *p<0.05; **p<0.01. 
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Furthermore, no significant alterations in IGF-1 levels were observed 
neither in brain cortex nor in hippocampus (Figure 4.8 A and B). 
 
Figure 4.8 – Effect of high-fat and/or low vitD diets in IGF-1 levels. Brain cortex 
(A) and hippocampus (B) IGF-1 levels. Data shown are the means ± SEM of 6 
animals from each condition studied. 
 
4.6 – High-fat and low vitD diets do not affect IDE protein 
levels 
 
One of the principal functions of insulin degrading enzyme (IDE) is, as 
its name suggests, the degradation of insulin, regulating the activation of its 
downstream pathways. Here, we observed that IDE levels were not altered, 
neither in the brain cortex nor in the hippocampus (Figure 4.9 A and B). 
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Figure 4.9 – Effect of high-fat and/or low vitD diets in IDE levels. Brain cortex (A) 
and hippocampus (B) IDE levels and western blot representative images (C). Data 
shown are the means ± SEM of 3-5 animals from each condition studied. 
 
4.7 – High-fat and low vitD diets modulates insulin 
receptor substrate 2 phosphorylation  
 
In the presence of insulin, IR phosphorylates IRS proteins that activate 
the PI3K/AKT pathway. In this line, we evaluated ρIRS1 levels and no 
significant alterations were observed in our experimental groups. However, 
GK rats exposed to low vitD presented a slight increase in its phosphorylation 
levels in brain cortex (Figure 4.10 A) while in hippocampus no significant 
alterations were observed (Figure 4.10 B).  
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Figure 4.10 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus IRS1 phosphorylation. Brain cortex (A) and hippocampus (B) 
IRS1/IRS1 levels and western blot representative images (C). Data shown are the 
means ± SEM of 3-5 animals from each condition studied.  
 
On the other hand, phosphorylation of IRS2 was significantly increased 
in brain cortex of GK HFD rats when compared with GK group. In respect to 
low vitD diet, in brain cortex, by itself it did not induce any alterations but 
together with HFD it lead to a decrease in pIRS2 levels when compared with 
GK HFD (Figure 4.11 A). However, this alteration was not conserved in 
hippocampus. By opposite, when HFD and low vitD diet were combined, it 
seemed to slightly increase IRS2 phosphorylation (Figure 4.11 B).  
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Figure 4.11 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus IRS2 phosphorylation. Brain cortex (A) and hippocampus (B) 
IRS2/IRS2 levels and western blot representative images (C). Data shown are the 
means ± SEM of 3-7 animals from each condition studied. Statistical significance: 
*p<0.05. 
 
Moreover, c-Jun N-terminal kinase protein (JNK) is a stress-activated 
kinase that inhibits IRS1 phosphorylation decreasing the activation of insulin 
pathways. In accordance with IRS1/IRS1 levels, no significant alterations 
were observed JNK/JNK levels in brain cortex (Figure 4.12 A), although a 
tendency to decrease JNK/JNK levels were observed in low vitD and HDF 
brain cortex. In the hippocampus, low vitD alone or in combination with HFD 
induced a slight decrease in the phosphorylation levels of JNK (Figure 4.12 
B). 
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Figure 4.12 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus JNK phosphorylation. Brain cortex (A) and hippocampus (B) 
JNK/JNK levels and western blot representative images (C). Data shown are the 
means ± SEM of 3-7 animals from each condition studied.  
 
4.8 – High-fat diet increases ERK activation while low vitD 
diet decreases its activation 
 
 ERK phosphorylation gives us an idea about MAPK pathway activation, 
since it is responsible for several cellular processes activated in response to 
stimuli that modulate gene expression, and cell growth, proliferation, 
differentiation, survival and apoptosis. Interestingly, we observed a significant 
decrease in ERK activation, in both brain cortex and hippocampus of rats 
exposed to low vitD alone or combined with HFD (Figure 4.13 A and B).  
[Chapter 4 – Results] 
 
 60 
On the other hand, HFD seems to induce the opposite effect, promoting an 
increase in ERK phosphorylation in both brain cortex and in hippocampus 
(Figure 4.13 A and B). 
 
Figure 4.13 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus ERK phosphorylation. Brain cortex (A) and hippocampus (B) 
ERK/ERK levels and western blot representative images (C). Data shown are the 
means ± SEM of 7 animals from each condition studied. Statistical significance: 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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4.9 – High-fat and low vitD diets interfere with PI3K 
pathway  
 
 PI3K/AKT is one of the main pathways activated by insulin. 
Consequently, we analyzed the levels of PI3K, AKT, AMPK and mTOR. No 
significant alterations in PI3K (p110) levels were observed in both brain cortex 
and hippocampus (Figure 4.14 A and B).  
 
Figure 4.14 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus PI3K (p110) levels. Brain cortex (A) and hippocampus (B) PI3K 
(p110) levels and western blot representative images (C). Data shown are the means 
± SEM of 7 animals from each condition studied.  
 
However, a decrease in AKT/AKT was observed in brain cortex of GK 
rats treated with HFD (Figure 4.15 A) while low vitD diet alone or combined 
with HFD decreased hippocampal AKT/AKT levels but only reached 
statistical significance when HFD was combined with low vitD (Figure 4.15 
B). 
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Figure 4.15 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus AKT phosphorylation. Brain cortex (A) and hippocampus (B) 
AKT/AKT levels and western blot representative images (C). Data shown are the 
means ± SEM of 6-7 animals from each condition studied. Statistical significance: 
*p<0.05; **p<0.01. 
 
Concerning to AMPK activation, a significant decrease was observed in 
in the brain cortex and hippocampus of all groups of animals, this effect being 
more pronounced when low vitD was combined with HFD (Figure 4.16 A and 
B).  
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Figure 4.16 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus AMPK phosphorylation. Brain cortex (A) and hippocampus (B) 
AMPK/AMPK levels and western blot representative images (C). Data shown are 
the means ± SEM of 7 animals from each condition studied. Statistical significance: 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
 
Furthermore, it is known that AMPK is responsible for the inhibition of 
mTOR activity that in turn regulates IRS1 phosphorylation, and insulin 
signaling pathway. Regarding the activation of mTOR, a slight increase in 
brain cortex of the HFD group was observed (Figure 4.17 A). However, this 
increase was only statistically significant in the hippocampus, when compared 
with low vitD treated group (Figure 4.17 B). In the hippocampus, low vitD 
attenuates the increase in ρmTOR/mTOR levels promoted by HFD (Figure 
4.17 B). 
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Figure 4.17 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus mTOR phosphorylation. Brain cortex (A) and hippocampus (B) 
mTOR/mTOR levels and western blot representative images (C). Data shown are 
the means ± SEM of 6 animals from each condition studied. Statistical significance: 
**p<0.01. 
 
4.10 – High-fat and low vitD diets affect CREB and PKA 
levels 
 
cAMP, an important biological second messenger, is widely described 
as being involved in the activation of several proteins such as AMPK, CREB 
and PKA. In our study, we observed that cAMP levels did not present any 
statistically significant alteration in brain cortex and hippocampus, although 
the combination of low vitD and HFD decreased slightly the levels of cAMP in 
brain cortex (Figure 4.18 A and B).  
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Figure 4.18 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus cAMP levels. Brain cortex (A) and hippocampus (B) cAMP levels. 
Data shown are the means ± SEM of 3-5 animals from each condition studied.  
 
CREB is a transcription factor highly associated with synaptic plasticity 
and long-term memory, being activated by AKT and cAMP. The activation 
pattern of CREB was different in brain cortex and hippocampus. Specifically, 
in brain cortex there was an increase in CREB/CREB levels, reaching 
statistical significance in HFD low vitD group when compared with GK rats 
(Figure 4.19 A). In hippocampus, the opposite occurs, with a significant 
decrease observed in the HFD low vitD group when compared with GK rats 
(Figure 4.19 B).  
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Figure 4.19 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus CREB phosphorylation. Brain cortex (A) and hippocampus (B) 
CREB levels and western blot representative images (C). Data shown are the 
means ± SEM of 6-7 animals from each group studied. Statistical significance: 
*p<0.05. 
 
PKA is a protein kinase also regulated by cAMP levels and it is also 
involved in synaptic plasticity and memory. Here, despite the absence of 
alterations observed in cAMP, a decrease in active PKA levels was observed 
in both brain cortex and hippocampus of HFD and HFD low vitD groups when 
compared with the GK group (Figure 4.20 A and B). Interestingly, low vitD 
diet alone also induced a decrease in PKA activity in the hippocampus. 
Moreover, in the hippocampus, HFD induced a lower decrease in PKA levels 
than that promoted by low vitD (Figure 4.20 B).  
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Figure 4.20 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus PKA levels. Brain cortex (A) and hippocampus (B) active PKA levels. 
Data shown are the means ± SEM of 6 animals from each condition studied. 
Statistical significance: *p<0.05; ***p<0.001; ****p<0.0001. 
 
4.11 – High-fat and/or low vitD diets promote GSK3β 
activation, p35 and p25 levels alterations and Tau protein 
hyperphosphorylation 
 
The insulin pathway can also regulate GSK3β activity, a kinase that is 
intimately related with the neuropathological hallmarks of AD such as tau 
hyperphosphorylation and A formation. In present study no significant 
alterations were observed in the levels of GSK3 inactive form in brain cortex 
(Figure 4.21 A) while in the hippocampus the combination of low vitD and 
HFD promoted a significant decrease in the levels of GSK3 inactive form, 
when compared with HFD group (Figure 4.21 B). No significant alterations 
were observed in GSK3 active form in both brain cortex and hippocampus 
(Figure 4.22 A and B).  
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Figure 4.21 – Effect of high-fat and/or low vitD diets in GSK3 phosphorylated 
at serine 9 (inactive form) in brain cortex and hippocampus. Brain cortex (A) and 
hippocampus (B) GSK3(ser9)/GSK3 levels and western blot representative 
images (C). Data shown are the means ± SEM of 7 animals from each condition 
studied. Statistical significance: *p<0.05. 
 
 
Figure 4.22 – Effect of high-fat and/or low vitD diets GSK3 phosphorylated at 
tyrosine 216 (active form) in brain cortex and hippocampus. Brain cortex (A) and 
hippocampus (B) GSK3(y216)/GSK3 levels and western blot representative 
images (C). Data shown are the means ± SEM of 7 animals from each condition 
studied.  
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 Besides GSK3β, the complex cyclin-dependent kinase 5 (CDK5)-p25 
can also be responsible for tau phosphorylation. Concerning CDK5 levels, no 
significant alterations were observed in both brain cortex and hippocampus, 
although HFD seem to induce a slight decrease in CDK5 levels in brain cortex 
(Figure 4.23 A and B). 
 
Figure 4.23 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus CDK5 levels. Brain cortex (A) and hippocampus (B) CDK5 levels and 
western blot representative images (C). Data shown are the means ± SEM of 7 
animals from each condition studied.  
 
However, although not statistically significant, brain cortex from GK low 
vitD and GK HFD low vitD groups presented an increase in p35 levels (Figure 
4.24 A) On the other hand, in hippocampus p35 levels are significantly 
decreased in GK HFD low vitD group when compared with GK and GK HFD 
groups (Figure 4.24 B).   
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Figure 4.24 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus p35 levels. Brain cortex (A) and hippocampus (B) p35 levels and 
western blot representative images (C). Data shown are the means ± SEM of 6 
animals from each condition studied. Statistical significance: *p<0.05. 
 
Concerning p25 levels, a significant decrease in the levels of this 
protein were observed in brain cortex in HFD rats when compared with GK 
and GK low vitD groups (Figure 4.25 A). However, in hippocampus a 
significant increase in p25 levels in GK low vitD diet animals occurred when 
compared with GK rats being this effect attenuated by the combination with 
HFD  (Figure 4.25 B).  
[Chapter 4 – Results] 
 71 
 
Figure 4.25 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus p25 levels. Brain cortex (A) and hippocampus (B) p25 levels and 
western blot representative images (C). Data shown are the means ± SEM of 6 
animals from each condition studied. Statistical significance: *p<0.05; **p<0.01. 
 
We next evaluated tau phosphorylation levels and we observed that in 
brain cortex, HFD induces an increase in the levels of tau phosphorylated at 
serine 396 residue when compared with GK rats, while in threonine 181 the 
increase is only statistically significant when compared with GK low vitD rats 
(Figure 4.26 A and C). A similar pattern was also observed in the 
hippocampus (Figure 4.26 B and D). No significant alterations were induced 
by low vitD (Figure 4.26 A - D).  
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 Figure 4.26 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus Tau phosphorylation. Brain cortex Tau(ser396)/Tau (A); 
hippocampus Tau(ser396)/Tau (B); brain cortex Tau(thr181)/Tau (C); 
hippocampus Tau(thr181)/Tau (D) and western blot representative images (E). Data 
shown are the means ± SEM of 7 animals from each condition studied. Statistical 
significance: *p<0.05; **p<0.01; ***p<0.001.  
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Additionally, the levels of A1-42, whose increased accumulation is a 
feature of degenerative brains, namely AD, were also measured and no 
alterations in this parameter were observed neither in brain cortex nor in 
hippocampus of our experimental groups (Figure 4.27 A and B). 
 
 
Figure 4.27 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus A1-42 levels. Brain cortex (A) and hippocampus (B) A1-42 levels. 
Data shown are the means ± SEM of 7 animals from each condition studied.  
 
4.12 – High-fat and low vitD diets decrease cholesterol 
levels but do not affect synaptic integrity 
 
 In order to evaluate synaptic integrity, the levels of cholesterol and of 
three synaptic markers were determined. Brain is the most cholesterol-rich 
organ and its regulation seems to be extremely important for correct synapse 
formation and function (Orth and Bellosta, 2012). Furthermore, cholesterol 
levels can also be regulated by insulin (Suzuki et al., 2010). When compared 
with low vitD group, a decrease in brain cortex cholesterol levels was 
observed in the HFD low vitD group (Figure 4.28 A). However, in 
[Chapter 4 – Results] 
 
 74 
hippocampus no statistically significant differences were observed (Figure 
4.28 B). 
 
Figure 4.28 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus cholesterol levels. Brain cortex (A) and hippocampus (B) cholesterol 
levels. Data shown are the means ± SEM of 8 animals from each condition studied. 
Statistical significance: *p<0.05. 
 
Concerning the synaptic integrity markers, we evaluate the levels of 
synaptophysin, a protein present in presynaptic vesicles, synaptosomal-
associated protein 25 (SNAP25), which helps the docking of presynaptic 
vesicles in order to release neurotransmitters to the synapse, and post-
synaptic density protein 95 (PSD95) that is present on postsynaptic density. 
No significant alterations were observed in both brain cortex and 
hippocampus exposed to the different dietary regimens (Figure 4.29 A-F). 
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Figure 4.29 – Effect of high-fat and/or low vitD diets in brain cortex and 
hippocampus synaptic markers. Brain cortex (A) and hippocampus (B) 
synaptophysin levels; brain cortex (C) and hippocampus (D) SNAP25 levels; brain 
cortex (E) and hippocampus (F) PSD95 levels and western blot representative 
images (G). Data shown are the means ± SEM of 7 animals from each condition 
studied.
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5.1 – Discussion 
 
Our work reveals that high-fat and/or low vitamin D diets affect insulin-
mediated signaling pathways in the diabetic brain, which may increase the 
risk of neurodegeneration. 
Insulin resistance is a common feature of T2D and metabolic syndrome 
(Umegaki, 2012, Moreira, 2013, Hussain et al., 2014), a situation that can be 
aggravated by poor diets (e.g. high intake of fats) and lack of physical 
exercise (Zimmet et al., 2001, American Diabetes, 2014).  Insulin resistance 
underlies several diabetes-associated complications, including alterations in 
the biochemistry, structure and function of CNS (Sima, 2010). It was already 
demonstrated that insulin resistance plays a key role in neuronal degeneration 
and loss (Hussain et al., 2014), which may affect several cognitive functions, 
particularly learning and memory abilities (Cardoso et al., 2009, Candeias et 
al., 2012, Duarte et al., 2012). In fact, T2D has been considered a major risk 
factor for vascular dementia and AD (Sebastiao et al., 2014).  
Interestingly, hypovitaminosis D has been associated not only with 
diabetes (Norman et al., 1980, Hirani et al., 2014, Reddy et al., 2015) but also 
with dementia (Evatt et al., 2008). In fact, vitD is involved in neuromodulation, 
neuroprotection and neurotrophic support (Eyles et al., 2013, Annweiler et al., 
2014) sharing similar functions with insulin (Alkharfy et al., 2013). 
In this study we used GK rats, an animal model of non-obese T2D, 
exposed to distinct diets (standard, low vitD, HFD and low vitD + HFD) as 
previously referred. We started by performing a systemic characterization of 
the animals to evaluate the impact of the diets. GK rats presented an increase 
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in fasting glycemia and HbA1C and a significant decrease in body weight, as 
previously reported (Duarte et al., 2000, Santos et al., 2014). Although HFD 
only promoted a slight increase in HbA1C and body weight, it significantly 
increased the levels of plasma total and non-HDL cholesterol and 
triglycerides, which is in accordance with previous studies (Srinivasan et al., 
2005, Petrov et al., 2015). In the literature we can find several effects of HFD 
depending on the duration and composition of the diet and animal model. A 
previous study showed that distinct HFD (42% energy; fat sources: HF-L - 
lard; HF-O - olive oil; HF-C - coconut fat; HF-F - fish oil) induced dissimilar 
alterations in Wistar rats; while HF-L and HF-O fed rats showed the most 
pronounced obesity and insulin resistance, insulin sensitivity in HF-C and HF-
F was close to normal (Buettner et al., 2006). Lee and coworkers (2011) 
showed that wild type mice fed a short-term HFD developed insulin resistance 
and presented increased body weight and deposition of lipid content in liver 
and skeletal muscle. More recently, it was demonstrated that HFD-induced 
obese rats do present insulin resistance but not increased serum free fatty 
acids (Jiang et al., 2015). Interestingly, our study demonstrated that low vitD 
attenuated HFD-induced increased body weight and total cholesterol, non-
HDL and triglycerides levels. Although low levels of serum vitamin D are 
associated with obesity and diabetes in humans (Liel et al., 1988), a study 
performed in vitD deficient rats showed that these animals present less body 
weight gain and lower amounts of visceral fat when compared with control 
rats (Bhat et al., 2014). In our study, the low vitamin D diet did not affect blood 
glucose. Although some evidence exists demonstrating that low levels of 
serum vitamin D are associated to high blood glucose levels (Kostoglou-
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Athanassiou et al., 2013, Hirani et al., 2014), this relation remains a matter of 
debate. Also our rats fed a low vitD diet did not present alterations in 
triglycerides levels, which confirm the observations made by De Novellis and 
coworkers (1994).  
For a long time, brain was considered an insulin-insensitive organ. 
Nowadays, it is widely accepted the fundamental role of insulin in CNS and 
disturbed insulin signaling is associated with altered cerebral biochemistry, 
structure and function (Cardoso et al., 2009). Although most of the insulin 
present in the brain is of peripheral origin, there is also a local production of 
this hormone (Cardoso et al., 2009, Duarte et al., 2012). 
We evaluated insulin signaling in brain cortex and hippocampus 
because these structures are highly enriched in insulin receptors and also 
VDR (Eyles et al., 2005), are intimately involved in learning and memory 
processes and are target areas in T2D and AD (Cardoso et al., 2009). Our 
study revealed that in brain cortex low vitD diet and HFD increase the levels 
of insulin, while in the hippocampus only HFD and the combination HFD and 
low vitD increases the levels of the hormone. These alterations seem to 
indicate a central insulin resistance resembling the peripheral 
hyperinsulinemia that occur in early stages of T2D. It was demonstrated that 
peripheral HFD induces a secondary hyperinsulinemia (Pratchayasakul et al., 
2011) as a response to insulin resistance that later will evolve to a state of 
hypoinsulinemia due to pancreatic -cells dysfunction and consequent failure 
of insulin production (Butler et al., 2003). So, we hypothesize that in our 
animals, a compensation mechanism is occurring in an attempt to overcome 
central insulin resistance (Liu et al., 2015a). 
[Chapter 5 – Discussion] 
 
 82 
IGF-1 is a growth factor that can exert insulin-like functions and can 
also activate IR (Duarte et al., 2012). Nevertheless, no significant alterations 
were observed in the levels of this growth factor. It was previously reported 
that IGF-1 levels are downregulated in the heart of streptozotocin (STZ)-
induced T1D rats (Jiang and Steinle, 2010) and friend virus-b type mouse 
(FVB) mice under HFD (Zhang et al., 2012). Cheng and colleagues (2003) 
also found decreased IGF-1 messenger ribonucleic acid (mRNA) levels in the 
temporal cortex of mice under ketogenic HFD. But, as said above, different 
experimental protocols and models may lead to distinct observations. 
Concerning vitD, it was shown that adolescents with severe vitD deficiency 
present low plasma levels of IGF-1 (Soliman et al., 2014) and vitD 
supplementation was shown to increase IGF-1 levels (Hypponen et al., 2008, 
Ameri et al., 2013). More studies are necessary to better understand the 
effects of HFD and low vitD IGF-1 levels, particularly in the brain. 
The action of insulin is a process under tight regulation. IDE is a zinc 
metallopeptidase that degrades intracellular insulin, and thereby terminates 
insulin activity, as well as participating in intercellular peptide signaling by 
degrading diverse peptides such as glucagon, amylin, bradykinin, and Aβ 
(Kim et al., 2011). Deficiencies in this protein's function are associated with 
AD and T2D (Maianti et al., 2014). Although a previous study demonstrated 
that HFD fed wild-type mice presented lower levels of IDE in the hippocampus 
(Petrov et al., 2015), we did not observe any significant alterations induced by 
the diets.  
To properly exert their functions, insulin and IGF-1 bind to IR and IGF-
1R initiating a cascade of events. Of notice, under insulin resistant conditions 
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some tissues or organs may compensate by increasing IR and/or IGF-1R 
expression (Sesti, 2000), a situation that was observed in the brain cortex of 
rats exposed to the combination HFD and low vitD. Interestingly, in the same 
group of animals a significant decrease in VDR levels was observed. Because 
vitD share similar functions with insulin (Deeb et al., 2007, Vuolo et al., 2012), 
the increase in IR levels may compensate for the decrease of VDR levels. It 
was also reported that VDR mutant mice suffer premature aging (Keisala et 
al., 2009), suggesting that the loss of VDR in the brain may accelerate brain 
cortex aging predisposing to neurodegenerative events. It was previously 
reported that under chronic inflammation, a characteristic of T2D, a 
significantly decreased VDR expression was observed in lung tissue (Agrawal 
et al., 2012), suggesting that in our study the lower levels of VDR could reflect 
a chronic inflammation of brain cortex. In accordance with our observations, 
Pratchayasakul and coworkers (2011) did not find alterations in IR levels in 
the hippocampus of HFD fed Wistar rats. Concerning IGF-1R, although it was 
previously showed an increase in brain cortex of HFD fed Sprague-Dawley 
rats (Cheng et al., 2003), our results revealed no alterations in the levels of 
this receptor induced by the diets. No significant alterations were observed in 
low vitD fed rats. As far as we know, there is no literature dealing with vitD 
and IGF-1R levels in the brain.  
 When insulin binds to IR, IRS1 and IRS2 are phosphorylated in order 
to further activate downstream pathways. Our results showed no alterations in 
IRS1 levels in any of the studied conditions however, a significant increase 
in IRS2 levels was observed in brain cortex of HFD rats. Previous studies 
have demonstrated that IRS2 in endothelial cells plays a crucial role in 
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pancreatic insulin secretion (Hashimoto et al., 2015). Perhaps in brain cortex 
increased IRS2 may help in insulin synthesis or action. Concerning the 
hippocampus, our observations are in accordance with those of Petrov et al 
(2015), showing that HFD fed mice hippocampus do not have significant 
alterations in IRS levels.  
Diabetes and obesity are associated with an increased activation of the 
stress-response kinase JNK (Kaneto et al., 2005). However, we did not 
observed significant alterations in JNK. It should be noted that we are 
comparing the effects of low vitD diet and/or HFD in brain insulin signaling of 
T2D brains. The lack of significant alterations observed in our study may 
simply demonstrate that our diets were insufficient to aggravate T2D-
associated alterations. 
Nevertheless, we observed a significant increase in ERK levels in 
brain cortex and hippocampus of HFD fed rats, which is in accordance with 
the observations made by Petrov and coworkers (2015). On the other hand, 
low vitD alone or in combination with HFD lead to a decrease in activation of 
ERK. Indeed, it was previously shown that vitD could be involved in the 
activation of this pathway since it was observed that vitD supplementation in 
T-helper cells was responsible for an increase in ERK (Nanduri et al., 2015). 
Consistent with the unaltered ρIRS1 levels we did not observe 
differences in the activation of PI3K among all groups of rats. Besides insulin, 
also vitD has been shown to activate PI3K (Wu and Sun, 2011). It was 
previously reported an increase in PI3K levels in the hypothalamus of 4-week-
old FVB/N mice fed a HFD for 19 weeks an effect that was not yet observed 
after 4 weeks of treatment (Metlakunta et al., 2008). Thus, we can speculate 
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that PI3K activation may be differently modulated depending on the stages of 
disease progression. Interestingly, although we did not observed significant 
differences in PI3K (p110) levels, AKT was decreased in the brain cortex of 
GK rats fed a HFD. In the hippocampus, AKT levels decreased in low vitD 
plus HFD diet fed rats.  
These results are in agreement with previous studies demonstrating a 
decreased activation of AKT in the heart of STZ-induced diabetic rats (Jiang 
and Steinle, 2010) and in the hippocampus of wild-type mice fed a HFD 
(Petrov et al., 2015). A decrease in AKT was also observed in the amygdala 
of diet-induced obese rats (Castro et al., 2013). Another study demonstrated 
that in 7-week-old male C57/BL mice exposed to a high energy diet the 
expressions of PI3K and AKT protein in brain tissue were significantly lower 
than those of the control group after 30 weeks of treatment (Ma et al., 2014). 
Interestingly, high-fat diet-induced, insulin-dependent PI3K activation in 
neurons of ventromedial hypothalamus contributes to obesity development 
(Klockener et al., 2011). 
AKT activation leads to a negative regulation of AMPK, through the 
regulation of ATP levels. AMPK is an energy sensor and plays a role in insulin 
sensitivity and glucose homeostasis (Tao et al., 2010). A decrease in AMPK 
activation was observed in both brain cortex and hippocampus of low vitD diet 
and/or HFD. These observations are in agreement with a previous study 
(Lindholm et al., 2013) demonstrating that HFD decreased AMPK activation in 
adipose tissue, heart and liver of Sprague-Dawley rats. Also Greig and 
coworkers (2015) reported that the aortic tissue of alipoprotein E (ApoE) -/- 
mice on high fat diet for 6 weeks present a decrease in AMPK activation. 
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Similarly, HFD-induced obese mice presented a decreased activation of 
AMPK in the hippocampus (Wang et al., 2015). It was also reported that 1,25-
dyhydroxyvitamin D₃ attenuated rotenone-induced neurotoxicity in SH-SY5Y 
cells through induction of autophagy, a phenomenon that also involves 
increased expression of AMPK (Jang et al., 2014). VitD in skeletal muscle 
was shown to improve muscle function, mass and strength (Teegarden and 
Donkin, 2009). AMPK is also able to increase glucose uptake from exercise 
(Teegarden and Donkin, 2009), raising the hypothesis that vitD is able to 
improve insulin sensitivity through AMPK-dependent glucose uptake. 
The PI3K/AKT pathway activates several proteins including mTOR 
(Scott et al., 1998), a protein involved in protein synthesis and cell growth 
(Vander Haar et al., 2007). The measurement of mTOR phosphorylation 
levels is one of the best ways to assess its activation and in our study we 
observed an increase in mTOR activation in the hippocampus of HFD fed GK 
animals, an effect that was abolished by low vitD. A previous study from our 
laboratory showed an increase in mTOR phosphorylation in GK rats brain 
cortex (Santos et al., 2014). There is evidence of increased mTOR activation 
in the liver of mice under HFD (Korsheninnikova et al., 2006). Also HFD fed 
rainbow trout showed increased activation of mTOR in the liver and 
hypothalamus (Libran-Perez et al., 2015). Evidence concerning the effects of 
low vitD in mTOR activation is scarce, with few studies showing a decrease in 
mTOR activation in HL60 cancer cells (Wu and Sun, 2011). It was also shown 
that 1,25(OH)2D3 protects β cells against high glucose-induced apoptosis 
through mTOR suppression (Yang et al., 2015) while in murine C2C12 
skeletal myotubes it enhances mTOR activation enhances the stimulating the 
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effect of leucine and insulin on protein synthesis (Salles et al., 2013).  Of 
notice, mTOR phosphorylation can occur in different residues and we only 
measured the phosphorylation of serine 2448, the most common residue.  
The activation of PI3K pathway inhibits GSK3 activation and in insulin 
resistance conditions an increased activation of this protein is observed 
(Dokken et al., 2008). In our study no significant alterations were observed, 
except for the significant decrease in GSK3 inactivation (phosphorylation of 
serine 9) observed in the hippocampus of low vitD plus HFD fed rats. An 
increase GSK3 activation was observed in the hippocampus of wild-type rats 
and C57BL/6 mice fed a HFD (Petrov et al., 2015). In this line, Sharma and 
Taliyan (Sharma and Taliyan, 2014) observed that indirubin-3'-monoxime, a 
GSKβ inhibitor, plays a neuroprotective role in HFD-induced cognitive 
impairment in mice, suggesting that GSK3β inhibition could prove to be 
beneficial in insulin resistant conditions. As far as we know, no studies exist 
concerning the role of vitD in GSK3β activation. 
GSK3β plays a key role in tau phosphorylation and Aβ production. We 
did not find significant alterations in the levels of Aβ1-42. A similar observation 
was made in the hippocampus of HFD fed wild-type rats treated (Petrov et al., 
2015). However, several other studies demonstrate that diabetes and insulin 
resistant conditions are associated with increased levels of Aβ (Carvalho et 
al., 2012, Son et al., 2012). Although we did not find a pronounced alteration 
in the activity of GSK3β, a significant increase in tau phosphorylation was 
observed in both brain cortex and hippocampus of HFD fed rats, an effect that 
was avoided when HFD was combined with low vitD. Accordingly, it was 
previously shown that STZ-induced diabetic rats (Santos et al., 2014a) and 
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HFD fed mice (Julien et al., 2010) present increased levels of tau 
phosphorylation in the brain.  
CDK5 is a modulator of tau phosphorylation and APP maturation and 
when activated CDK5 converts p35 in p25 (Patrick et al., 1999). No significant 
alterations were observed in the levels of CDK5. However, a decrease in p35 
levels was observed in hippocampus of GK rats treated with HFD low vitD 
diet. Concerning p25 levels a decrease was observed in the brain cortex of 
HFD rats and an increase in the hippocampus of low vitD diet fed rats, 
reflecting brain area specific alterations. Teegarden and coworkers (2009) 
showed an increase in CDK5 levels in ventral striatum of HFD fed mice. 
Furthermore, in hippocampus of HFD fed wild-type rats p35 levels were 
increased (Petrov et al., 2015). Also, vitD was shown to increase p35 levels in 
HL60 cancer cell-line (Chen et al., 2004). p25 can form a complex with CDK5 
promoting tau hyperphosphorylation. In fact in AD patients, p25 is increased 
(Patrick et al., 1999), which may support our observations concerning the 
increase in p25 in low vitD diet fed mice. In fact, low serum levels of vitD are 
commonly observed in AD patients (Przybelski and Binkley, 2007, Evatt et al., 
2008, Littlejohns et al., 2014). These results seem to be in contradiction with 
tau phosphorylation levels however, we should note that tau can be 
phosphorylated in several residues and we only measured the 
phosphorylation at serine 396 and threonine 181. 
cAMP is involved in several cellular processes including the insulin 
signaling pathway and synaptic plasticity (Rivera et al., 2015). Also, it is 
associated with A levels regulation (Rivera et al., 2015). In brain cortex a 
slight decrease in cAMP was observed in low vitD, HFD fed rats. Makar and 
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coworkers (1995) reported that T2D db/db mice had reduced ability to 
synthesize cAMP. It is also known that vitD stimulates the activity of adenylyl 
cyclase, responsible for cAMP production (Deeb et al., 2007), which lead us 
to hypothesize that the low vitD diet can also contribute for the decrease in 
cAMP levels. 
CREB, a well-known transcription factor responsive to cAMP, has 
many functions in many different organs, and some of its functions have been 
studied in relation to the brain. In fact, CREB has a well-documented role in 
neuronal plasticity and long-term memory formation (Silva et al., 1998). In our 
study CREB levels increased significantly in brain cortex of rats exposed to 
low vitD combined to HFD while in the hippocampus the opposite was 
observed. It was previously shown that CREB mRNA levels decreased in 
HFD fed Sprague-Dawley rats hippocampus (Molteni et al (2002), although no 
alterations were observed in brain cortex. Accordingly, Miao and coworkers 
(2015) showed that the hippocampal levels of CREB are decreased in 
diabetic rats and 3 month-old C57BL/6J mice exposed to HFD for 12 weeks 
showed a suppression of the ERK/CREB pathway in the brain (Liu et al., 
2015). Also, mouse skeletal muscle cells supplemented with vitamin D 
showed an enhancement of CREB levels through ERK activation (Ronda et 
al., 2007), these results being in accordance with our observations.  
PKA, whose activity in dependent on cAMP levels, is also involved in 
memory formation and synaptic plasticity (Rivera et al., 2015). Our study 
revealed that PKA activation is decreased in both brain cortex and 
hippocampus of rats fed a HFD and/or low vitD diet. It was previously reported 
that disturbances of CaMKII/PKA/PKC phosphorylation in the hippocampus is 
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an early change that may be associated with the development and 
progression of diabetes-related cognitive dysfunction (Liao et al., 2013). 
However, impaired working memory and hippocampal LTD deficits in juvenile-
onset diabetes mellitus rats were shown to be associated with an excessive 
PKA activity, which may play a role in altered NMDA receptor function and 
impaired LTD (Sacai et al., 2014). Recently, it was demonstrated that learning 
and memory deficits of STZ-induced diabetic rats were ameliorated by the 
administration of vitD (Calgaroto et al., 2014, Moghadamnia et al., 2015) 
corroborating the idea that vitD play a key role in cognitive function. However, 
we must be aware that distinct patterns of PKA activation may occur 
depending on the causes and duration of the diabetic status.  
Cholesterol is essential for neuronal physiology: it is a major 
component of cell membranes and precursor of steroid hormones, it 
contributes to the regulation of ion permeability, cell shape, cell-cell 
interaction, and transmembrane signaling (Vance, 2012). Defects in brain 
cholesterol metabolism may contribute to neurological syndromes such as 
AD, and even to the cognitive deficits typical of the old age (Refolo et al., 
2000). A significant decrease in brain cortex cholesterol was observed in low 
vitD, HFD fed rats suggesting that these animals are more susceptible to 
neurodegenerative events. However, no significant alterations were observed 
in the hippocampus, which is in accordance with a previous study (Granholm 
et al., 2008). 
The brain depends upon glucose as its main source of energy, and 
tight regulation of glucose metabolism is critical for brain physiology. Glucose 
is transported across the cell membranes by facilitated diffusion mediated by 
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Gluts (Glut 1 mainly in brain endothelial and glial cells; Glut 3 and Glut 4 
mainly in neuronal cells) (Duelli and Kuschinsky, 2001). Interestingly, we 
observed alterations in the levels of insulin sensitive and insensitive Gluts. 
The decrease in Glut 4 (insulin sensitive) was the most pronounced alteration 
in both brain cortex and hippocampus. Also, the levels of the partially insulin 
sensitive Glut 3 decreased in the hippocampus of rats fed the HDF diet alone 
or combined with low vitD. These alterations possible reflect the disturbances 
in insulin signaling, as previously discussed. In fact, it was previously shown 
that HFD fed C57BL/6J mice presented decreased expression and plasma 
membrane localization of the insulin-sensitive neuronal glucose transporters 
Glut 3/Glut 4 (Liu et al., 2015) as well as reduced adipose tissue Glut 4 mRNA 
expression (McAllan et al., 2013). In skeletal muscle of HFD fed rats a 
decrease in Glut 4 levels was also observed (Tremblay et al., 2001). Another 
study showed that the brain cortex of HFD fed rats do not present alterations 
in Glut 3 and Glut 1 mRNA levels (Cheng et al., 2003). But some 
compensations also seem to happen: an increase in Glut 3 levels in the brain 
cortex of rats fed a HFD combined with low vitD and an increase in Glut 1 
levels in low vitD fed rats. However, it was previously reported that Glut 3 
mRNA expression in brainstem might be activated by vitamin D (Peeyush 
Kumar et al., 2011). But we must be aware that mRNA expression does not 
always correlate with protein levels. 
Adequate ATP production and regulation of the metabolic processes 
are essential for the maintenance of synaptic transmission and neuronal 
function. Brain’s function depends on the maintenance of synaptic integrity 
and plasticity, processes that are highly affected in AD and T2D-associated 
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neurodegeneration (Cardoso et al., 2009, Correia et al., 2012, Moreira, 2013, 
Carvalho et al., 2015). In order to evaluate the impact of diets-induced 
alterations discussed above, we evaluated the levels of 3 synaptic integrity 
markers: synaptophysin, SNAP25 and PSD95. We did not observe 
statistically significant alterations in the levels of those markers. Accordingly, 
previous studies reported no significant alterations in the levels of those 
synaptic markers in brain cortex (Julien et al., 2010) and hippocampus (Bhat 
and Thirumangalakudi, 2013) of HFD fed mice. However, Arnold and 
collaborators (Arnold et al., 2014) found decreased expression of PSD95 and 
synaptopodin, an actin-associated protein enriched in spine apparatuses in 
brain cortex of HFD mice. Also vitamin D supplementation has been shown to 
improve synaptic function (Latimer et al., 2014). 
In summary, our work shows that low vitD and/or HFD disturb(s) 
insulin-mediated signaling pathways in T2D brains. However, some 
compensation mechanisms seem to occur that may help overcome the 
metabolic changes induced by those diets. Although the diets-induced 
alterations potentially increased the susceptibility to neurodegenerative 
processes and cognitive deficits (e.g. increase in tau protein phosphorylation) 
no changes in synaptic integrity were detected. In fact, we can find many 
contradictory observations in the literature, which may result from different 
durations and composition of the diets and different animal models. We 
hypothesize that more pronounced effects would be observed in older rats 
and/or by increasing the duration of the diets. Another interesting observation 
is that both brain cortex and hippocampus behave differently demonstrating 
brain-structure specific susceptibilities. However, more studies are warranted 
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to elucidate the impact of excessive consumption of fats and deficiency in vitD 
in brain biochemistry, structure and function. 
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